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Summary
1. After intracisternal administration, 6-hydroxydopamine had a greater
effect on brain noradrenaline than on dopamine.
2. Administration of two doses of 6-hydroxydopamine increased the deple-
tion of noradrenaline but not of dopamine.
3. Small doses of 6-hydroxydopamine decreased the concentration of nor-
adrenaline with little or no effect on dopamine. Tyrosine hydroxylase activity
was not reduced with these treatments.
4. While pargyline pretreatment offered no advantage in the depletion of
brain noradrenaline after 6-hydroxydopamine, depletion of brain dopamine was
greatly potentiated by this treatment. The reduction of striatal tyrosine
hydroxylase activity observed after 6-hydroxydopamine was also potentiated by
pargyline pretreatment.
5. The amounts of labelled noradrenaline and dopamine formed from 3H-
tyrosine were greatly reduced by 6-hydroxydopamine treatment. After 3H-
DOPA, formation of noradrenaline was greatly reduced while formation of
labelled dopamine was only moderately reduced suggesting that decarboxyla-
tion of DOPA can occur in other than catecholamine containing neurones.
6. Desmethylimipramine and imipramine inhibited depletion of noradrenaline
produced by 6-hydroxydopamine but did not alter depletion of dopamine.
Reserpine did not inhibit depletion of catecholamines produced by 6-hydroxy-
dopamine.
7. Administration of 6-hydroxydopamine to developing rats lowered both
noradrenaline and dopamine concentrations as well as the tyrosine hydroxylase
activity in the brains of these animals.
Introduction
Depletion of the catecholamine content of sympathetically innervated tissues by
6-hydroxydopamine was reported several years ago (Porter, Totaro & Stone, 1963;
Laverty, Sharman & Vogt, 1965). From the observation that 6-hydroxydopamine
caused an enduring depletion of tissue noradrenaline, Porter et al. (1963) suggested
that this compound might destroy noradrenaline binding sites. Recently, several
workers have extended these observations and found that 6-hydroxydopamine
actually causes degeneration of peripheral adrenergic nerves (Tranzer & Thoenen,
1968; Thoenen & Tranzer, 1968 ; Malmfors & Sachs, 1968).
Brain catecholamines and 6-hydroxydopamine
These reports indicating that 6-hydroxydopamine produces a chemical sympa-
thectomy peripherally soon led to investigations of the possibility that this compound
might also. produce destruction of brain catecholamine neurones after being injected
into brain (Ungerstedt, 1968; Bloom, Algeri, Groppetti, Revuetta & Costa, 1969;
Uretsky & Iversen, 1970; Breese & Traylor, 1970). Examination of areas rich in
adrenergic neurones with electron microscopy has indicated that 6-hydroxydopamine
can indeed produce degeneration of central noradrenergic fibres (Bloom et al., 1969).
Support for this view was extended in reports that indicated that tyrosine hydroxy-
lase activity was reduced in the caudate nucleus and other parts of brain after
6-hydroxydopamine administration (Breese & Traylor, 1970; Uretsky & Iversen,
1970).
The purpose of our experiments was to examine further the effects of 6-hydroxy-
dopamine in depleting catecholamines from brain, to define the effects of multiple
injections of 6-hydroxydopamine at several doses, and to determine the effect of
various psychoactive drugs known to alter uptake, storage and metabolism of
catecholamines on brain amine depletion produced by 6-hydroxydopamine.
Methods
Male Sprague-Dawley rats (140-200 g) received 25-200 jg of 6-hydroxydopamine
intracisternally in 25 tul of saline solution as described previously (Schanberg,
Schildkraut, Breese & Kopin, 1968; Breese, Kopin & Weise, 1970). The saline
solution contained 04 mg/ml of ascorbic acid to prevent oxidation of the 6-hydroxy-
dopamine; animals which did not receive 6-hydroxydopamine received the saline
solution containing ascorbic acid.
After killing the animals by cervical fracture, brains were removed, homogenized
in 0-4 N perchloric acid and the homogenates kept frozen until they were analysed.
After thawing and centrifugation of the homogenate, brain noradrenaline and
dopamine were isolated according to the procedure of Anton & Sayre (1962). Nor-
adrenaline was assayed according to the method of Haggendal (1963); dopamine
according to the method of Anton & Sayre (1964).
Some animals received 50 tuCi of 3H-tyrosine (347 Ci/mmol) or 100 uCi of
3H-DOPA (3 0 Ci/mmol) intravenously. Animals were killed 1 h after injecting the
labelled compounds and the radioactive noradrenaline and dopamine was isolated
according to the method of Sedvall, Weise & Kopin (1968). All radioactivity was
measured using scintillation spectrometry; an internal standard of 3H-toluene was
used to correct for counting efficiency.
The ' striatum ' was dissected from brain on a chilled glass plate and refers to
that area of brain adjacent to the lateral ventricle and bounded by the radiation of
the corpus callosum. Access to this mass was obtained through the lateral ventricle
after hemisection of the whole brain. Tyrosine hydroxylase was isolated from these
tissues according to the method of Musacchio, Julou, Kety & Glowinski (1969).
Enzyme activity was determined by the method of Nagatsu, Levitt & Udenfriend
(1964). For the measurement of enzyme activity in the striatum half quantities of
each reagent were used with the final volume measuring 0-5 ml.
At 13 days of age, rat pups were injected intracisternally with 100 jug of 6-hydroxy-
dopamine; 26 days later the animals were killed. Brains were divided sagittally
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along the midline; one-half of the brain from each animal was analysed for nor-
adrenaline and dopamine and the other half for tyrosine hydroxylase.
Several drugs were used in combination with intracisternally administered
6-hydroxydopamine (100 pg). These included pargyline (50 mg/kg), desmethyl-
imipramine (25 mg/kg), imipramine (25 mg/kg), chlorpromazine (25 mg/kg), and
D-amphetamine (10 mg/kg). All of the compounds were administered intraperi-
toneally 30 min before 6-hydroxydopamine. Metaraminol (100 yg) was adminis-
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FIG. 1. Comparison of the effect of one dose (@- ) with that of two doses (0---0)
of 6-hydroxydopamine on brain noradrenaline (A) and dopamine (B). Animals received
6-hydroxydopamine intracisternally. The rats given one dose were killed 2 weeks later. When
two doses were administered, they were separated by 1 week, the first dose being given 2 weeks
before the animals were killed. The animals which received only one dose received a saline
injection 1 week after the first injection. Control values for brain noradrenaline were 330 ± 32
ng/g and 592±42 ng/g for dopamine. Vertical bars indicate the S.E.M. Each point represents
six to eight determinations.
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tered intracisternally 15 min before the 6-hydroxydopamine. Reserpine (5 mg/kg)
was administered 18 h before a second dose of 2 5 mg/kg. The 6-hydroxydopamine
was administered 3 h after the last dose of reserpine.
The 6-hydroxydopamine HBr was purchased from Regis Chemical Company.
Pargyline was kindly supplied by Abbott Laboratories. The D-amphetamine and
chlorpromazine were gifts of Smith, Kline & French Laboratories. The desmethyl-
imipramine and imipramine were kindly furnished by Geigy Laboratories. The
reserpine was a gift from Ciba Laboratories. 3H-Tyrosine and 3H-DOPA were
purchased from Amersham-Searle Corporation.
Results
Catecholamine content in rat brain after 6-hydroxydopamine treatment
Noradrenaline and dopamine contents were determined in rat brain 14 days after
the intracisternal administration of various doses of 6-hydroxydopamine. In
confirmation of earlier studies (Uretsky & Iversen, 1970; Breese & Traylor, 1970),
6-hydroxydopamine had a greater effect on noradrenaline than dopamine (Fig. 1).
The dose of 25 ,ug reduced noradrenaline approximately 35% and 200 yg approxi-
mately 63%. Dopamine was not significantly altered at the smaller doses of
6-hydroxydopamine but was reduced 49% at the higher dose. A linear dose-
response relation was noted for the depletion of both amines (Fig. 1).
The effect of multiple dose administration was also determined. A comparison
of one dose with two doses is also shown in Fig. 1. Two injections significantly
enhanced the depletion of brain noradrenaline. Dopamine depletion, on the other
hand, was not increased by the second dose of 6-hydroxydopamine (Fig. 1). At a
dose of 25 jug of 6-hydroxydopamine, noradrenaline depletion increased with an
additional dose while dopamine concentrations remained unaltered by this procedure
(Figs. 1 & 2). To determine if this depletion of noradrenaline might be increased
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FIG. 2. Effect of multiple doses of 6-hydroxydopamine on brain concentrations of noradrena-
line 0l, dopamine * and on tyrosine hydroxylase IZ activity. Animals were given doses of
6-hydroxydopamine intracisternally 1 week apart and killed 1 week after the last dose. Control
values for noradrenaline and dopamine were 352±18-1 and 658±35-8 ng/g respectively.
Tyrosine hydroxylase activity was (4 40 pmol/mg)/h in the control animals. Values represent
the mean from six to ten animals. Significance when compared with controls * P<0C001
** P<005.
91
92 G. R. Breese and T. D. Traylor
further if additional small doses were administered, other multiple dose sequences
were studied (Fig. 2). As previously observed 2 times 25 1tg reduced the concentra-
tion of noradrenaline by 55% without having an effect on dopamine. Three injec-
tions of 25 jug caused a further small decrease in noradrenaline concentration, but
dopamine was now significantly reduced by 14%. Two doses of 25 jug with an
additional dose of 50 ,ug of 6-hydroxydopamine lowered the noradrenaline concen-
tration by 66% and the dopamine concentration was reduced by 25%. None of the
treatments significantly altered tyrosine hydroxylase activity.
Effect of pargyline on the dose-response relation of the reduction of
brain noradrenaline and dopamine by 6-hydroxydopamine
Previous studies have demonstrated that pargyline offered no advantage in the
reduction of brain noradrenaline by 6-hydroxydopamine but potentiated the reduc-
tion of cerebral dopamine by 6-hydroxydopamine at higher doses (Traylor & Breese,
1970). These results are reaffirmed in this study (Tables 3 & 4). Since it is well
established that a large portion of the cerebral dopamine is contained in the striatum
(Carlsson, 1959), the relation of the dose of 6-hydroxydopamine to the effect on
,dopamine as well as on tyrosine hydroxylase activity was examined in this brain
area (Fig. 3). As might have been expected, both dopamine and tyrosine hydroxy-
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'FIG. 3. Effect of 6-hydroxydopamine on the concentration of dopamine and tyrosine hydroxy-
lase activity in the striatum. Various doses of 6-hydroxydopamine were administered intra-
cisternally to animals with (0- -04) and without (@-) pargyline pretreatment.
Animals were killed 14 days later. Control value for striatal dopamine was 6~04±0~2 ,ig/g;
control tyrosine hydroxylase activity was (2le6 ±2-l pmol/mg)/hour. Mean values were
determined from groups of seven animals.
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lase were reduced in proportion to the dose of 6-hydroxydopamine. The reduction
of both was enhanced by pargyline treatment (Fig. 3) as already observed in whole
brain (Breese & Traylor, 1970).
A comparison of the effect of one dose with that of two doses of 6-hydroxy-
dopamine was also made in pargyline treated animals. In contrast to the effect on
cerebral noradrenaline without pargyline pretreatment (Fig. 1), two doses did not
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FIG. 4. Comparison of the effect of one dose (- *) with that of two doses (@--) of
6-hydroxydopamine in pargyline treated animals on brain noradrenaline (A) and dopamine (B).
Animals received various doses of 6-hydroxydopamine 30 min after being given pargyline;
1 week later one half of the group received saline and the other half 6-hydroxydopamine in
combination with pargyline. Brain noradrenaline and brain dopamine values for saline treated
controls were 360±40 and 582±39 ng/g respectively. Values represent the mean from six
animals. * P<0 001 when compared with the result from animals receiving a single dose of
6-hydroxydopamine.
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significantly enhance the reduction of the concentration of noradrenaline over a
single dose (Fig. 4). The reduction of dopamine after two injections was signifi-
cantly greater than after a single injection at the 100 ,ug dose level (Fig. 4). At a
dose of 200 fag, the reduction of dopamine with a single dose was not signifi-
cantly different from that observed after two doses.
In our experience, two injections of 200 /g 6-hydroxydopamine, one with pargy-
line and the other without pargyline, produced the most consistent depletion of
brain catecholamines of any of the sequences tested. The effect on brain nor-
adrenaline, dopamine, and tyrosine hydroxylase was examined after treatment with
this sequence (Table 1). The concentration of brain noradrenaline was reduced by
88%, dopamine concentration by 87%, and tyrosine hydroxylase activity comparably
by 93%. This sequence is most routinely used in our laboratory to treat animals
for pharmacological experimentation.
Effect of 6-hydroxydopamine on the synthesis of catecholamines from
radioactively labelled DOPA and tyrosine
Synthesis of catecholamines from 3H-tyrosine and 3H-DOPA was determined 14
days after the intracisternal administration of 6-hydroxydopamine (Table 2). The
amount of radioactively labelled noradrenaline and dopamine isolated from the
brains of animals treated with 6-hydroxydopamine after 3H-tyrosine was reduced
by 83 and 76% respectively, when compared with normal animals. The amount of
labelled noradrenaline in the brain of 6-hydroxydopamine treated rats after 3H-
DOPA was as low as that seen in the animals that received 3H-tyrosine. In con-
trast to these results, the amount of radioactive dopamine isolated from the brains
of rats treated with 6-hydroxydopamine and which received 3H-DOPA was only
33% lower than in normal animals, considerably less than the reduction for
dopamine observed after 3H-tyrosine administration (Table 2).
Effect of various agents on the depletion of brain catecholamines by
6-hydroxydopamine
To obtain some insight into the mechanism by which 6-hydroxydopamine may
cause neuronal degeneration, various pharmacological agents known to influence
TABLE 1. Effect of two doses of 6-hydroxydopamine, one dose with and one without pargyline pretreat-
ment, on the concentrations of catecholamines and on tyrosine hydroxylase activity in the rat brain
Treatment Noradrenaline Dopamine Tyrosine hydroxylase
ng/g ng/g (pmol/mg)/h
Control 433±20-6 658±35 8 5-35±032
6-Hydroxydopamine 45± 6-8* 85±11-8* 0-36±0-08*
Animals received two doses of 200 pg of 6-hydroxydopamine intracisternally 1 week apart; the firstdose was in combination with pargyline (50 mg/kg) and the second dose without pargyline. Animals
were killed 2 weeks after the last dose. Values represent the mean±s.E.M. from nine animals.
*P<000O when compared with controls.
TABLE 2. Effect of 6-hydroxydopamine on the synthesis of 3H-catecholamines from 3H-tyrosine and
3H-dopa
Isotope Treatment 3H-Noradrenaline 3H-Dopamine
3H-Tyrosine Saline 750±60 570±36
6-Hydroxydopamine 128 ±25* 135±25*
3H-DOPA Saline 577 ±66 330±17
6-Hydroxydopamine 87± 7-3* 219±10*
Animals were given either 3H-tyrosine (40 pCi) or 3H-DOPA (80 pCi) intravenously 14 days after
6-hydroxydopamine (2 x 200,ug). Values expressed as c.p.m./brain±s.E.M. *P<0.001 when compared
with controls.
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different aspects of the mechanisms that control neuronal function were administered
before the intracisternal administration of 6-hydroxydopamine (Table 3). Com-
pounds previously shown to inhibit uptake of noradrenaline into brain (Schanberg,
Schildkraut & Kopin, 1967), desmethyl imipramine and imipramine, inhibited the
depletion of noradrenaline produced by 6-hydroxydopamine. Metaraminol and
amphetamine, phenylethylamine derivatives, likewise inhibited the reduction of the
concentration of noradrenaline produced by 6-hydroxydopamine. Chlorpromazine
inhibited the effect of 6-hydroxydopamine but less so than the other compounds.
In contrast, neither pargyline nor reserpine altered the noradrenaline depletion pro-
duced by this dose schedule of 6-hydroxydopamine.
Dopamine was also determined after several treatments (Table 4). In contrast
to their effect on noradrenaline depletion, desipramine, imipramine and chlor-
promazine had no effect on the dopamine depletion induced by 6-hydroxydopamine.
As noted in an earlier study (Breese & Traylor, 1970), pargyline significantly en-
hanced the depletion of brain dopamine. Reserpine produced a similar effect to
that of pargyline enhancing the reduction of brain dopamine by 6-hydroxydopamine.
TABLE 3. Effect of various agents on the depletion of brain noradrenaline by 6-hydroxydopamine
Noradrenaline
Treatment Dose ng/brain Percent control
Saline 245±10-7 34.2±1'5,
Pargyline 50 252±19-3 35-2±2-7
Desipramine 25 529±35 8 74 0±5-0
Imipramine 25 496±32-9 69-4±4-6*
Chlorpromazine 25 391 432-2 54-7±4-5*
Metaraminol loot 543±35 0 75.9±4-9*
Amphetamine 10 590±29-3 82.5±4.1*
Reserpine 7-5 234±24-3 32-7±3-4
All animals received 100 jLg of 6-hydroxydopamine intracistemally and were killed 21 days later.
tDrug doses are expressed as mg/kg for all compounds except metaraminol which was given intra-
cistemally and is expressed as ,ug/brain. The values represent the mean±s.E.M. from eight-twelve
animals. The mean control value for animals which did not receive 6-hydroxydopamine was 715 ±35
ng/brain. *P<0.001 when compared with saline treatment.
TABLE 4. Effect of various agents on the depletion of brain dopamine by 6-hydroxydopamine
Dopamine
Treatment Dose ng/brain Percent control
Saline 526±50 57-6±4-8
Pargyline 50 333 ±42 36.4±4.6*
Desipramine 25 530±45 57-9±4-9
Imipramine 25 537±35 58-7±3-8
Chlorpromazine 25 491 ±38 53-7±4-1
Metaraminol loot 815±37 89-1 ±4-0*
Reserpine 7.5 340±24 37-2±3-4*
All animals received 100 ug of 6-hydroxydopamine intracisternally and were killed 21 days later.
tDrug doses are expressed as mg/kg for all compounds except metaraminol which was given intra-
cistemally and is expressed as /tg/brain. Values represent the mean±s.E.M. from eight-twelve animals.
The control value for dopamine was 915 ±41 ng/brain. *P<0.001 when compared to saline treatment.
TABLE 5. Brain dopamine, noradrenaline and tyrosine hydroxylase after 6-hydroxydopamine
administration to developing rats
Treatment Noradrenaline Dopamine Tyrosine hydroxylase
ng/g ng/g (pmol/mg)/h
Saline (control) 346±15-7 654±41-6 7-15±0-51
6-Hydroxydopamine 119± 7-5* 207±59* 1.62±0.52*
6-Hydroxydopamine (100,Ag) was injected intracistemally to rats 13 days after birth. Animals were
killed 26 days later. All values are the mean±S.E.M. from five-six animals. *P<0.001 when compared
with corresponding control.
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Administration of 6-hydroxydopamine to developing rats
Animals, 13 days old, were given 100 tg of 6-hydroxydopamine int-racisternally.
The brains were analysed and the results compared with those obtained with saline
treated controls after the animals were maintained for 26 days. At this time, the
concentrations of noradrenaline and dopamine, and tyrosine hydroxylase activity
were determined (Table 5). The concentration of brain noradrenaline was lowered
by 66%/ and the dopamine concentration was 32% of control. Tyrosine hydroxy-
lase activity was significantly reduced to 23% of control.
Discussion
Several laboratories have clearly indicated that 6-hydroxydopamine produces a
profound and long lasting depletion of brain catecholamines after being adminis-
tered into the brain (Uretsky & Iversen, 1970; Breese & Traylor, 1970). This
depletion has been accompanied by a fall in brain tyrosine hydroxylase activity
(Uretsky & Iversen, 1970; Breese & Traylor, 1970) as well as by observable ultra-
structural changes in central adrenergic neurones indicative of degenerating fibres
(Bloom et al., 1969; Bartholini, Richards & Pletscher, 1970). Inhibition of synthe-
sis of ca!echolamines from labelled tyrosine has also been observed (Anagnoste,
Backstrom & Goldstein, 1969; Breese & Traylor, 1970). Such observations are
similar to results obtained in the periphery after 6-hydroxydopamine treatment
(Tranzer & Thoenen, 1968; Mueller, Thoenen & Axelrod, 1969) and in the caudate
nucleus after making a lesion in the substantia nigra (Hokfelt & Ungerstedt, 1969).
This information is consistent with the viewpoint that 6-hydroxydopamine can in-
deed produce destruction of catecholamine containing neurones after being ad-
ministered into brain.
A previous report (Breese & Traylor, 1970) indicated that pargyline enhanced
the depletion of brain dopamine by 6-hydroxydopamine while offering no advan-
tage to the depletion of brain noradrenaline. This observation was confirmed in
our study (Tables 3 & 4). As might have been expected, the reduction in the con-
centration of dopamine and tyrosine hydroxylase activity in the striatum by
6-hydroxydopamine was also enhanced by pargyline pretreatment (Fig. 3). The
original viewpoint associated with combining 6-hydroxydopamine and pargyline
was to prevent deamination of 6-hydroxydopamine since several reports have indica-
ted that pargyline will spare the metabolism of a variety of amines (Schanberg
et al., 1968; Breese, Chase & Kopin, 1969). However, the lack of further depletion
of noradrenaline in animals given 6-hydroxydopamine and pargyline might not
support this reasoning. Thus, it is not yet clear whether the increased depletion of
dopamine by 6-hydroxydopamine in pargyline treated animals is directly related
to inhibition of monoamine oxidase or to some other pharmacological action of
pargyline (Breese, Chase & Kopin, 1970).
Bartholini et al. (1970) recently reported that a small dose of 6-hydroxydopamine
injected into the cerebral ventricle lowered the concentrations of brain catechol-
amines without inducing any ultrastructural damage that could be observed with
electron-microscopy. In our study, the administration of several small doses of
6-hydroxydopamine caused a significant depletion of catecholamines without a
comparable reduction of tyrosine hydroxylase activity. Since denervation has
been associated with a reduction in tyrosine hydroxylase activity (Mueller et al.,
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1969), perhaps this lack of correlation in our study bwtween amine depletion and
enzyme reduction may also reflect a disruption of neuronal mechanisms thus per-
mitting amine depletion without ultrastructural destruction (Bartholini et al., 1970).
The effects of various drugs have been studied by several investigators to deter-
mine if the action of 6-hydroxydopamine on peripheral adrenergic fibres might be
altered (Porter et al., 1963; Bennett, Burnstock, Cobb & Malmfors, 1970). In our
study, reserpine did not diminish the reduction of brain noradrenaline (Table 3).
This is in agreement with the earlier work of Porter et al. (1963) on the heart.
Since reserpine is believed to block the ATP-Mg++ dependent uptake mechanism
in storage granules (Carlsson & Waldeck, 1965), Bennett et al. (1970) have suggested
that neuronal storage is not a prerequisite for axonal damage by 6-hydroxy-
dopamine. The enhanced depletion of dopamine observed after 6-hydroxydopamine
in reserpine treated animals may be similar to the increased effectiveness of
6-hydroxydopamine observed on noradrenergic stores in the periphery after reser-
pine administration (Bennett et al., 1970). Both imipramine and desipramine in-
hibited noradrenaline depletion by 6-hydroxydopamine without altering the reduc-
tion of brain dopamine (Table 4). Recently, Evetts & Iversen (1970) have reported
similar findings using protriptyline. These results probably reflect the ability of
these compounds to inhibit amine uptake by noradrenaline-containing neurones
(Carlsson & Waldeck, 1965; Schanberg et al., 1967), but not by dopaminergic
fibres (Fuxe & Ungerstedt, 1968). Since phenylethylamine derivatives like
metaraminol have a differential effect on brain catecholamines after intracisternal
injection (Breese et al., 1970), it was puzzling to find that metaraminol had an
inhibitory effect on 6-hydroxydopamine depletion of both dopamine and nor-
adrenaline. Additional studies to determine the effects of other drugs on the deple-
tion of catecholamines by 6-hydroxydopamine would seem worthwhile since a pro-
cedure which drastically reduces brain noradrenaline without affecting dopamine
would seem desirable.
The development of monoamine systems in the rat has been studied by Agrawal,
Glisson & Himwich (1966). Our interest in the administration of 6-hydroxydopamine
to developing animals was to determine if neuronal damage to noradrenergic
neurones would occur before they were totally developed. Strong support for the
view that neuronal damage occurred was to be found in the reduction of tyrosine
hydroxylase and catecholamines 26 days after administration of 6-hydroxydopamine
(Table 5). This may be comparable to the results reported for destruction of the
peripheral sympathetic system when administered postnatally to developing rats
(Angeletti & Levi-Montalcini, 1970).
Several reports indicate that the gross appearance of rats treated with 6-hydroxy-
dopamine is not greatly altered (Bloom et al., 1969; Breese & Traylor, 1970;
Uretsky & Iversen, 1970). Treated animals also appear to have normal activity
(Burkard, Jalfre & Blum, 1969; Evetts, Uretsky, Iversen & Iversen, 1970) as well
as the ability to control body temperature in the cold (Breese, Howard & Moore,
unpublished observations). Furthermore, while chronic treatment with 6-hydroxy-
dopamine has not altered operant behaviour performance, it has caused a signifi-
cant decrease in response rate in self-stimulating animals (Leahy & Breese, un-
published observations). Studies are in progress to further evaluate the behaviour
of animals treated with 6-hydroxydopamine.
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